REGN7508 and REGN9933 to prevent blood clots in people with a PICC line
Tests REGN7508 and REGN9933 against placebo for preventing venous thromboembolism in people with a PICC.
Key facts
- Who runs it
- Regeneron Pharmaceuticals
- Where
- Georgia, Greece, and Spain10 sites in 3 countriesChoose a country to see its sites
- Trial code
- Registry title
- Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 1,908 people, planned
- Started
- 7 Sept 2026
- Expected to end
- 18 Sept 2029
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- REGN7508
- REGN9933
- Placebo
- Record updated
- 29 September 2026
Who can take part
The trial is looking for people aged 15 years or older who are getting a PICC, a thin tube put into an arm vein to receive medicines. It tests whether REGN7508 or REGN9933 prevents blood clots, compared with placebo.
- Age
- 15 years and older
- Sex
- All sexes
- Disease stage
- People getting a PICC for medicines given into a vein, such as chemotherapy, antibiotics or TPN (feeding through a vein). Daily activity level must be ECOG 3 or better, or a similar level.
- Earlier treatment
- People cannot join if they already have a central vein catheter, or a catheter in the spine or epidural space, during screening.
- Biomarker or test result
- INR and aPTT blood clotting tests no more than 25% above the upper limit. Body weight at least 40 kg (88 lb).
- Main reasons for not taking part
- Earlier blood clot in the arm or chest veins on the side where the PICC will go
- Acute leukemia, myelodysplastic syndrome, or myelofibrosis
- Cancer of the gut, food pipe, urinary or genital organs that has not been removed by surgery
- Brain tumor or cancer spread to the brain, now or in the past
- Major heart or blood vessel event in about the past 30 days
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Is undergoing PICC placement for Intravenous (IV) administration of clinically indicated medications, including chemotherapy, antibiotics, TPN, and/or other indications as described in the protocol
- Has Eastern Cooperative Oncology Group Performance (ECOG) Status ≤3 or equivalent functional status as described in the protocol
- Has International Normalization Ratio (INR) and aPTT values no more than 25% above the upper limit as described in the protocol
- Weighs at least 40 kg during the screening period
Who cannot take part
- Has a history of prior venous thrombosis in the arm and/or ipsilateral thoracic central veins in which the PICC is to be placed
- Has any major cardiovascular event within approximately the past 30 days prior to study administration
- Has acute leukemia, myelodysplastic syndrome, or primary and secondary myelofibrosis
- Has unresected luminal gastrointestinal (GI) (including esophageal) or unresected genitourinary (GU) malignancy
- Has current or history of known brain tumors or brain metastases
- Pre-existing central venous catheter or indwelling spinal or epidural catheter during the screening period; Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Venous thromboembolism
This trial is currently available in Georgia.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have a tube placed in a vein to receive treatment (called Peripherally Inserted Central Catheter [PICC]). Patients with PICCs have a higher risk of getting blood clots which can block the veins (this is called Venous Thromboembolism [VTE]) and lead to serious health problems or be life threatening.
Read full original descriptionShow less
The aim of the study is to see how well REGN7508 and REGN9933 prevent blood clots compared to placebo after PICC placement and to see if these medications cause certain types of bleeding.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects) * If the study drugs affect the ability of the blood to clot normally
The 3 groups in the trial
- REGN7508Treatment being tested
- REGN9933Treatment being tested
- PlaceboPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Master Protocol for a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, for Prophylaxis of Venous Thromboembolism in Participants With a Peripherally Inserted Central Catheter (PICC) (ROXI-PEAK)
- Plain-language title
- REGN7508 and REGN9933 to prevent blood clots in people with a PICC lineGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 19 November 2026.
- Criteria questions
- Built from NCT07697599, who can take part
- Record updated
- 29 September 2026